There are 2789 resources available
636P - A comparative analysis of prostate cancer short-term recurrence risk forecast performance between 8-gene signature and commercial panels
Presenter: Jinan Guo
Session: ePoster Display
933P - Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
Presenter: Jean-Luc van Laethem
Session: ePoster Display
934P - The TARGET study: A global investigation of advanced dosimetry for transarterial radioembolization of hepatocellular carcinoma with yttrium-90 glass microspheres
Presenter: Marnix Lam
Session: ePoster Display
935P - An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma
Presenter: Feng Bi
Session: ePoster Display
936P - Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC)
Presenter: Zhenggang Ren
Session: ePoster Display
1033TiP - A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Presenter: Kyriakos Papadopoulos
Session: ePoster Display
1022P - Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
Presenter: Vladimir Alifanov
Session: ePoster Display
939P - Phase II study of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC)
Presenter: David Hsiehchen
Session: ePoster Display